Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

Via Pharmaceuticals, Inc.

David Robert Bolin

Yimin Qian

Matthew Michael Hamilton

Weiya Yun

Adrian Wai-Hing Cheung

Fariborz Firooznia

Lee Apostle McDermott

Jenny Tan

Steven Gregory Mischke

Waleed Danho

Arthur M Felix

Johannes A Meienhofer

Lin Yi

Stuart Hayden

Nicholas Marcopulos

Iou-Iou Sytwu

Shaoqing Chen

Christophe Michoud

Kshitij Chhabilbhai Thakkar

Margaret O'Donnell

Shoaqing Chen

Shiming Li

Lee Aopstle McDermott

Nicholas Marcopulous

Provided herein are compounds of the formula (I): were RI is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a -4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of trigliceride. such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Inhibitors of diacylglycerol acyltransferase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators

Indole and indazole analogs as glycogen synthase activators

Aniline analogs as glycogen synthase activators

Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors

Compounds of formula (I) are provided,wherein Rand Rare as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

This invention relates to a novel process for the synthesis of vasoactive intestinal peptide analog Ac(1-31)-NH2 from four protected peptide fragments.

Synthesis of VIP analog

Growing community of inventors

Montclair, NJ, United States of America

David Robert Bolin